Fractyl Health (GUTS) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Morgan Stanley Maintains Fractyl Health(GUTS.US) With Buy Rating, Maintains Target Price $10
Moomoo News06:31 ET · Ratings
Analysts Are Bullish on These NA Stocks: BrightSpring Health Services, Inc. (BTSG), Fractyl Health, Inc. (GUTS)
TipRanks06:21 ET · Ratings
Earnings Call Summary | Fractyl Health(GUTS.US) Q4 2024 Earnings Conference
moomoo AI20:21 ET · Conference Call
Express News | Fractyl Health Inc: Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing
Reuters17:27 ET
Fractyl Health GAAP EPS of -$0.52 Misses by $0.18
Seeking Alpha16:23 ET
Fractyl Health | 8-K: Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
SEC16:13 ET · Announcements

Comments

Jaguar8

Jan 31 08:38

NEWS

$Fractyl Health (GUTS.US)$
Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025
Friday, 31st January at 8:01 am
Prioritizing Revita's clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing REMAIN-1 pivotal study; anticipate midpoint data analysis in Q2 2025 a...

71775255

Jan 13 08:50

$Fractyl Health (GUTS.US)$
stay away from this app alert

1

Jaguar8

Jan 13 06:01

NEWS

$Fractyl Health (GUTS.US)$
Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
Monday, 13th January at 7:00 am
Company also announces strong enrollment progress for REMAIN-1 weight maintenance pivotal study
High demand from patients and physicians indicates significant interest in REMAIN-1 study and GLP-1 discontinuation; mid-point analysis on-track and anticipa...

Jaguar8

Dec 12, 2024 06:03

NEWS

$Fractyl Health (GUTS.US)$
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
Thursday, 12th December at 7:00 am
RJVA-001 was successfully delivered in large animal Yucatan pig models at low total viral dose
Results confirm ability to directly target pancreas with novel delivery catheter and rout...

Trytosaveabit

Dec 9, 2024 06:27

On watch for data release! Note the dates this week!

$Fractyl Health (GUTS.US)$ BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will present new preclinical data from its Rejuva platform at the 2024 Poster Session of the 22nd World Congress Insulin Resistance, Diabetes & Cardiovascular Disease...

1

2

GUTS Fractyl Health

Trade Overview

Capital Trend

News

Comments

Trending Stocks